Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.
Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.
Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.
Location: United States
Employees: 11-50
Total raised: $287M
Founded date: 2018
Investors 4
| Date | Name | Website |
| 24.04.2022 | Aisling Ca... | aislingcap... |
| - | Lightchain... | lightchain... |
| 11.08.2022 | Alpha Wave... | alphawaveg... |
| 16.07.2021 | Abingworth... | abingworth... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.09.2025 | - | $115M | Fidelity M... |
| 15.07.2021 | Series B | $172M | - |
Mentions in press and media 19
| Date | Title | Description |
| 07.01.2026 | WashU Startups Draw Record $1.7 Billion In Private Investment As Commercialization Accelerates | Startup companies built on Washington University in St. Louis discoveries attracted a record $1.7 billion in private-sector investment over the past year, funding that WashU leaders say is speeding the path from campus research to diagnosti... |
| 05.09.2025 | Wugen Secures $115M: Off-the-Shelf CAR-T Fuels Cancer Fight | Wugen, a St. Louis-based biotech, secured $115 million in new funding. Fidelity Management led the significant investment round. The capital propels WU-CART-007, Wugen's cutting-edge allogeneic CAR-T cell therapy. This innovative "off-... |
| 04.09.2025 | Wugen: $115 Million Raised To Advance CAR-T For T-Cell Cancers | Wugen, a clinical-stage biotechnology company based in St. Louis, has announced the closing of a $115 million equity financing round. The investment, led by Fidelity Management & Research Company and joined by a consortium of life scien... |
| 28.08.2025 | Wugen Raises $115M in Funding | Wugen, a St. Louis, MO-based clinical-stage biotechnology company, raised $115M in funding. The round was led by Fidelity Management and Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, I... |
| 27.08.2025 | Wugen woos VCs, landing $115M to bring fratricide-resistant CAR-T cell therapy to market | Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first off-the-shelf CAR-T for T-cell malignancies. A pivotal trial is underway, putting the company on track to seek approval in 202... |
| 16.06.2022 | WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies | PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 16, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology co... |
| 20.07.2021 | Wugen Takes $172M For Tumor Treatments | San Diego-based Wugen, a biotechnology company which is developing treatments for solid tumors, recently annoucned a $172M, Series B funding round. The company--which says it licensed its technology from Washington University in St. Louis--... |
| 17.07.2021 | Wugen Raises $172M in Series B Funding | Wugen, a Sant Louis MO- and San Diego CA-based clinical stage biotechnology company, raised $172M in Series B funding. The round was led by Abingworth and Tybourne Capital Management with participation from Fidelity Management & Researc... |
| 15.07.2021 | Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials | Wugen, Inc., a clinical stage biotechnology company developing a pipeline of off-the-shelf cell therapies, today announced the completion of an oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management... |
| 15.07.2021 | New CEO, check. $172M round, check. Wugen's off-the-shelf cell therapies are ready for takeoff | Dan Kemp (Wugen) When Dan Kemp was plotting his next move after Takeda, he was “blown away” by data from Wugen, a biotech working on off-the-shelf natural killer (NK) cell therapies. Now, after four months in the CEO seat, he’s ready to tak... |
Show more